Medical News

RSS

Compugen third quarter net loss decreases to $3.6 million

Compugen Ltd. today reported financial results for the third quarter ending September 30, 2011.

9 Nov 2011

Neuromuscular training reduces noncontact lower extremity injuries in female athletes

Integrating a coach-led neuromuscular warm-up prior to sports practice appeared to reduce the risk of lower extremity injuries in female high school soccer and basketball athletes, according to a report in the November issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

9 Nov 2011

Viewpoints: Today's 'personhood' vote in Miss.; reactions to Romney's health care plan

What about in vitro fertilization, a process that both creates and discards embryos? What new rights would be afforded to a fetus, and how would those rights affect or compete with the rights of the woman who carries it? Would a woman who has an abortion be guilty of murder and subject to capital punishment? ... In their quest to ban abortion in Mississippi, the amendment's drafters appear to have rushed past such concerns.

9 Nov 2011

On Election Day, watching key ballot issues in Ohio, Mississippi

Voters across the nation will decide a host of statewide initiatives Tuesday and elect governors in Mississippi and Kentucky ... In battleground Ohio, voters will decide ... whether to prohibit people from being required to buy health insurance as part of the national health care overhaul.

9 Nov 2011

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2011, and provided a business update.

9 Nov 2011

First clinical trial that integrates LifeOnKey EHR, PHR with Target eCRF EDC software

Target Health Inc., and LifeOnKey Inc., are pleased to announce the initiation of the first clinical trial that integrates the LifeOnKey electronic health record (EHR) and Personal Health Record (PHR), with Target eCRF electronic data capture (EDC) software.

9 Nov 2011

Insmed third quarter revenues decrease to $0.4 million

Insmed Incorporated, a biopharmaceutical company, today reported financial results for the third quarter and nine-months ended September 30, 2011.

9 Nov 2011

Brazil leading fight against hunger, WFP head says

"Brazil is a world leader in the fight against hunger and its experience can be shared with other countries, visiting World Food Programme [WFP] chief Josette Sheeran said Monday ... in the northeastern city of Salvador while inaugurating a local branch of a newly established Center of Excellence Against Hunger based in the capital Brasilia," Agence France-Presse reports.

9 Nov 2011

SunLink first quarter consolidated net revenues increase 5.4% to $43,053,000

SunLink Health Systems, Inc. today announced a loss from continuing operations for its first fiscal quarter ended September 30, 2011 of $305,000, or a loss of $0.04 per fully diluted share, compared to a loss from continuing operations of $2,263,000, or a loss of $0.28 per fully diluted share for the quarter ended September 30, 2010.

9 Nov 2011

Men and overweight individuals eat faster, consume more

Two new studies by researchers at the University of Rhode Island are providing additional insights into the role that eating rate plays in the amount of food one consumes. The studies found that men eat significantly faster than women, heavier people eat faster than slimmer people, and refined grains are consumed faster than whole grains, among other findings.

9 Nov 2011

New poverty calculations show how health costs hurt seniors

The Census Bureau's analysis finds childhood poverty declining because of the CHIP health care program and supplemental nutrition efforts. But older Americans fare worse because of out-of-pocket health costs.

9 Nov 2011

Inhaling low levels of CO reduces impact of environmental stress

According to scientists, carbon monoxide (CO), a tasteless, colorless and odorless gas, is not only a danger to the environment but also highly toxic to human beings. Found in the exhaust of vehicles and generators, CO has been dubbed the "silent killer" because excessive inhalation is lethal, poisoning the nervous system and heart.

9 Nov 2011

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

Micromet third quarter total revenues decrease to $4.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

Cutting U.S. global health funding would slow progress, hurt development in other countries

A Minnesota Daily editorial states that a proposed nine percent cut in U.S. global health program funding "would drastically slow ... progress and hurt development and advancement in other countries," adding that "investing in the development of poor countries is good for everyone involved. When there are more highly educated, healthy countries, there is more prosperity for all."

9 Nov 2011

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011

Tornier third quarter sales increase 16% to $57.6 million

Tornier N.V., a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, reported sales of $57.6 million for the third quarter of 2011 compared to sales of $49.7 million for the third quarter of 2010, an increase of 16% as reported and 11% in constant currency.

9 Nov 2011